News & Updates

The topical phosphodiesterase 4 inhibitor PF-07038124 is safe and helps lower disease activity in patients with mild-to-moderate atopic dermatitis (AD) and plaque psoriasis, according to the results of a phase IIa study.

Treatment with intravenous ertapenem yields improvements in the clinical and inflammatory markers of hidradenitis suppurativa (HS), according to a retrospective study.

Among patients with metastatic basal cell carcinoma (mBCC), those with nodal disease appear to have a higher chance of remission, while individuals with distant metastasis tend to have persistent disease and subsequently die from it, a recent study reveals. However, the survival rates at 5 years surpass 50 percent even for those with stage IV disease.

A prospective, multicentre study has demonstrated the efficacy of patch tests (PTs) for patients who are being treated with dupilumab.

Smokers who have received a diagnosis of early-stage melanoma are at increased risk of death, according to a study.

Exposure to oil palm pollen poses a heightened risk of developing diseases such as asthma and allergic rhinitis in Asians or risk of exacerbations in those who have these diseases already, according to a study.

First-line treatment with rituximab appears to induce durable remission in patients with pemphigus, and this is achieved without corticosteroid therapy and any additional maintenance infusion of rituximab.